Anthera Pharmaceuticals Inc. (ANTH) Plunges 5.11%
Anthera Pharmaceuticals Inc. (ANTH) had a rough trading day for Tuesday April 16 as shares tumbled 5.11%, or a loss of $-0.0048 per share, to close at $0.09. After opening the day at $0.07, shares of Anthera Pharmaceuticals Inc. traded as high as $0.10 and as low as $0.07. Volume was 20,228 shares over 14 trades, against an average daily volume of n/a shares and a total float of 26.18 million.
As a result of the decline, Anthera Pharmaceuticals Inc. now has a market cap of $2.34 million. In the last year, shares of Anthera Pharmaceuticals Inc. have traded between a range of $0.40 and $0.01, and its 50-day SMA is currently $n/a and 200-day SMA is NA.
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Anthera Pharmaceuticals Inc. is based out of Hayward, CA and has some 21 employees. Its CEO is John Thompson.
Anthera Pharmaceuticals Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.